{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:19:19Z","timestamp":1791533959081,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41591-020-1082-2","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T12:05:43Z","timestamp":1601899543000},"page":"1557-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Richtig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-0478","authenticated-orcid":false,"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pakhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gusenleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Brase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gasal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239\u20131251 (2019).","journal-title":"Lancet Oncol."},{"key":"1082_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626\u2013636 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1082_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1082_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/pcmr.12834","volume":"33","author":"G McArthur","year":"2020","unstructured":"McArthur, G. et al. 5-Year survival update of cobimetinib plus vemurafenib in BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Pigment Cell Melanoma Res. 33, 148\u2013255 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"1082_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","volume":"130","author":"S Ugurel","year":"2020","unstructured":"Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition \u2013 update 2019. Eur. J. Cancer 130, 126\u2013138 (2020).","journal-title":"Eur. J. Cancer"},{"key":"1082_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies \u2013 update 2017. Eur. J. Cancer 83, 247\u2013257 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1082_CR7","doi-asserted-by":"publisher","first-page":"279ra241","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1082_CR8","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","volume":"21","author":"H Kakavand","year":"2015","unstructured":"Kakavand, H. et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin. Cancer Res. 21, 3140\u20133148 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1082_CR9","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386\u20131394 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1082_CR10","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","volume":"192","author":"JS Wilmott","year":"2014","unstructured":"Wilmott, J. S. et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J. Immunol. 192, 2505\u20132513 (2014).","journal-title":"J. Immunol."},{"key":"1082_CR11","doi-asserted-by":"publisher","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","volume":"7","author":"PA Ascierto","year":"2018","unstructured":"Ascierto, P. A. & Dummer, R. Immunological effects of BRAF + MEK inhibition. Oncoimmunology 7, e1468955 (2018).","journal-title":"Oncoimmunology"},{"key":"1082_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/labinvest.2016.132","volume":"97","author":"M Mandal\u00e0","year":"2017","unstructured":"Mandal\u00e0, M. et al. Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab. Invest. 97, 166\u2013175 (2017).","journal-title":"Lab. Invest."},{"key":"1082_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","volume":"10","author":"C Yu","year":"2019","unstructured":"Yu, C. et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front. Immunol. 10, 990 (2019).","journal-title":"Front. Immunol."},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","volume":"8","author":"S Kelderman","year":"2014","unstructured":"Kelderman, S., Schumacher, T. N. & Haanen, J. B. Acquired and intrinsic resistance in cancer immunotherapy. Mol. Oncol. 8, 1132\u20131139 (2014).","journal-title":"Mol. Oncol."},{"key":"1082_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto, P. A. et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase\u20093 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur. J. Cancer 126, 33\u201344 (2020).","journal-title":"Eur. J. Cancer"},{"key":"1082_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941\u2013946 (2019).","journal-title":"Nat. Med."},{"key":"1082_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 936\u2013940 (2019).","journal-title":"Nat. Med."},{"key":"1082_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929\u2013935 (2019).","journal-title":"Nat. Med."},{"key":"1082_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/pcmr.12834","volume":"33","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci, P. F. et al. Updated survival in patients with BRAF-mutant melanoma administered pemobrlizumab, dabrafenib, and trametinib. Pigment Cell Melanoma Res. 33, 148\u2013255 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"1082_CR20","doi-asserted-by":"crossref","unstructured":"McArthur, G. A. et al. Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: primary results from the phase\u20093 IMspire150 trial. In American Association for Cancer Research Virtual Annual Meeting I, abstract CT012 (2020).","DOI":"10.1158\/1538-7445.AM2020-CT012"},{"key":"1082_CR21","doi-asserted-by":"publisher","first-page":"VIII413","DOI":"10.1093\/annonc\/mdy288.032","volume":"29","author":"C-C Lin","year":"2018","unstructured":"Lin, C.-C. et al. Phase I\/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Ann. Oncol. 29, VIII413 (2018).","journal-title":"Ann. Oncol."},{"key":"1082_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin, J. et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J. Clin. Oncol. 36, 383\u2013390 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1082_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","volume":"86","author":"O Hamid","year":"2017","unstructured":"Hamid, O. et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur. J. Cancer 86, 37\u201345 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1082_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase\u20092 trial. Lancet Oncol. 16, 908\u2013918 (2015).","journal-title":"Lancet Oncol."},{"key":"1082_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"1082_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/pcmr.12834","volume":"33","author":"GV Long","year":"2020","unstructured":"Long, G. V. et al. Characteristics of long-term survivors and subgroup analyses with combination nivolumab plus ipilimumab for advanced melanoma (CheckMate 067). Pigment Cell Melanoma Res. 33, 148\u2013255 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"1082_CR27","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2019.37.15_suppl.9508","volume":"37","author":"C Osgood","year":"2019","unstructured":"Osgood, C. et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable metastatic melanoma (UMM) by therapy type. J. Clin. Oncol. 37, 9508 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1082_CR28","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1082_CR29","doi-asserted-by":"crossref","first-page":"CT037","DOI":"10.1158\/1538-7445.AM2019-CT037","volume":"79","author":"FS Hodi","year":"2019","unstructured":"Hodi, F. S. et al. Genomic analyses and immunotherapy in advanced melanoma. Cancer Res. 79, CT037 (2019).","journal-title":"Cancer Res."},{"key":"1082_CR30","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/1538-7445.AM2019-4217","volume":"79","author":"A Ribas","year":"2019","unstructured":"Ribas, A. et al. Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study. Cancer Res. 79, 4217 (2019).","journal-title":"Cancer Res."},{"key":"1082_CR31","doi-asserted-by":"crossref","unstructured":"Weber, J. S. et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann. Oncol. 30, V533\u2013V534 (2019).","DOI":"10.1093\/annonc\/mdz255"},{"key":"1082_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 21, 358\u2013372 (2020).","journal-title":"Lancet Oncol."},{"key":"1082_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 (2019).","journal-title":"Cancer Cell"},{"key":"1082_CR34","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","volume":"23","author":"RE Vilain","year":"2017","unstructured":"Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin. Cancer Res. 23, 5024\u20135033 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1082_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s40425-019-0797-4","volume":"7","author":"D Massi","year":"2019","unstructured":"Massi, D. et al. The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. J. Immunother. Cancer 7, 308 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1082_CR36","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann. Oncol. 28, 1130\u20131136 (2017).","journal-title":"Ann. Oncol."},{"key":"1082_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker, A. et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22, 567\u2013574 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1082_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13029-016-0060-z","volume":"11","author":"M Riester","year":"2016","unstructured":"Riester, M. et al. PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code Biol. Med. 11, 13 (2016).","journal-title":"Source Code Biol. Med."},{"key":"1082_CR39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/CCI.19.00130","volume":"4","author":"S Oh","year":"2020","unstructured":"Oh, S. et al. Reliable analysis of clinical tumor-only whole-exome sequencing data. JCO Clin. Cancer Inf. 4, 321\u2013335 (2020).","journal-title":"JCO Clin. Cancer Inf."},{"key":"1082_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajco.12656","volume":"12","author":"V Atkinson","year":"2016","unstructured":"Atkinson, V. et al. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pac. J. Clin. Oncol. 12, 5\u201312 (2016).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"1082_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/annonc\/mdu529","volume":"26","author":"AM Menzies","year":"2015","unstructured":"Menzies, A. M. et al. Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial. Ann. Oncol. 26, 415\u2013421 (2015).","journal-title":"Ann. Oncol."},{"key":"1082_CR42","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"1082_CR43","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"1082_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"1082_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1082_CR46","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"1082_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/bioinformatics\/btt767","volume":"30","author":"J Schroder","year":"2014","unstructured":"Schroder, J. et al. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics 30, 1064\u20131072 (2014).","journal-title":"Bioinformatics"},{"key":"1082_CR48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1082_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1082_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1082_CR51","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1082_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1082_CR53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"1082_CR54","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death\u20091 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102\u20134109 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1082-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:10:26Z","timestamp":1723716626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1082-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-1082-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.D. reports intermittent, project-focused consulting and\/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron and Alligator outside the submitted work. C.L. reports research funding from Roche and BMS, speakers bureau for Roche, BMS, MSD, Amgen, Novartis and Pierre Fabre, and consulting and advisory roles for BMS, MSD, Roche, Novartis, Merck Serono, Sanofi and Pierre Fabre. V.A. reports advisory roles for BMS, Merck Serono, MSD, Novartis, Roche, Nektar and Pierre Fabre, and received speaker\u2019s fees from BMS, Merck, MSD and Novartis, and travel support from BMS, MSD and Onco-Sec. M.M. reports consulting or advisory roles for MSD, Roche, BMS and Pierre Fabre and research funding from Roche, Novartis and BMS. P.D.N. reports advisory roles for BMS, Immunocore, Merck, MSD, Novartis and Pfizer, speaker\u2019s bureaux for BMS and Novartis and steering committee membership for Immunocore, Merck and Novartis. A.A. reports personal fees and other from BMS, MSD, Roche, Novartis, Merck, Sanofi, Amgen and Pierre Fabre, outside the submitted work. E.R. reports consulting or advisory roles for Amgen, Bayer, BMS, MSD, Merck, Novartis, Pierre Fabre, Roche and Sanofi; reception of honoraria from Amgen, Bayer, BMS, MSD, Merck, Novartis, Pierre Fabre, Roche and Sanofi; speaker\u2019s bureaux for Amgen, BMS, MSD, Merck, Novartis, Pierre Fabre and Sanofi; research funding from Amgen, BMS, MSD, Novartis, Pierre Fabre and Roche; travel support from Amgen, BMS, MSD, Merck, Novartis, Pierre Fabre, Roche and Sanofi; and President of the Austrian Cancer Aid\/Styria. N.Y. reports consulting and advisory roles for Novartis, Ono, BMS and MSD, honoraria from Novartis, Ono, BMS and MSD and institutional research support from Novartis, Ono, BMS, MSD and Takara-Bio. C.R. reports consulting or advisory roles for BMS, Roche, Amgen, Novartis, Pierre Fabre, MSD, Sanofi, Biothera, CureVac and Merck. D.S. reports research funding from Novartis and BMS. H.A.T. reports consulting or advisory roles for Novartis, BMS, Roche-Genentech, Merck and Array BioPharma and research funding from BMS, Novartis, Merck, GlaxoSmithKline, Genentech\/Roche and Celgene. P.A.A. reports consulting or advisory roles for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar and Boehringer Ingelheim, research funding from BMS, Roche-Genentech and Array and travel support from MSD. A.R. reports serving as a consultant\/independent contractor for, and being the recipient of honoraria from, Amgen, Chugai, Merck, Novartis and Sanofi; advisory roles and receipt of honoraria from Arcus, Bioncotech, Compugen, CytomX, ImaginAb, Isoplexis, Merus, Rgenix, Lutris, PACT Pharma and Tango Therapeutics; self-managed stock shareholder in Arcus, Compugen, CytomX and Merus; and research support from Agilent and BMS. K.T.F. reports advisory roles for Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, X4 Pharmaceuticals, PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Stattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros and Vibliome; consulting roles for Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre and Debiopharm; research funding from Novartis and Sanofi; and stock shareholder in Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, X4 Pharmaceuticals, PIC Therapeutics, Fount, Shattuck Labs, Apricity, Oncoceutics, Fog Pharma, Tvardi, xCures, Monopteros and Vibliome. N.P. reports employment at Novartis Healthcare Pvt. Ltd. C.D.C. reports employment with, and stock in, Novartis Pharmaceuticals. D.G. reports employment with Novartis Institutes for BioMedical Research. A.M. reports employment by Novartis and stock or ownership in Novartis and BMS. J.C.B. reports employment by, and stock ownership in, Novartis, and is a coinventor on a patent application related to reported biomarker subgroups of interest. E.G. reports employment by, and stock ownership in, Novartis. G.V.L. reports consultant advisory roles for Aduro Biotech, Inc., Pierre Fabre Medicament, BMS, Amgen, MSD, Novartis Pharma, Array BioPharma, Syneos and Sandoz Biopharmaceuticals. All authors received support for third-party medical writing and editorial assistance provided by ArticulateScience LLC and funded by Novartis Pharmaceuticals Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}